Department of Pathology and Laboratory Medicine, Rhode Island Hospital, The Alpert School of Medicine, Brown University, Providence, RI, U.S.A.
Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI, U.S.A.
Anticancer Res. 2014 Aug;34(8):3957-67.
While previous studies have described associations between specific microRNAs and colorectal cancer (CRC) metastasis, our understanding of microRNA regulation of metastatic spread remains largely unexplored. To identify microRNAs critical for disease progression, we measured microRNA expression in primary CRC tumors and synchronous liver metastases in 19 cases using quantitative polymerase chain reaction (qPCR) arrays. We identified 16 microRNAs significantly differentially expressed between primary tumors and liver metastases that distinguish primary tumors and liver metastases by hierarchical clustering. Combinations of microRNAs expressed in the primary tumor and in the metastatic tumor are associated with survival, but these signatures have no microRNAs in common. We found that increased expression of miR-210 and miR-133b in liver metastases compared to primary tumors is associated with lower survival. We propose that evaluating the change in expression between primary and metastatic tumors in each patient may lead to improved biomarker development.
虽然之前的研究已经描述了特定 microRNAs 与结直肠癌 (CRC) 转移之间的关联，但我们对 microRNA 调节转移扩散的理解在很大程度上仍未得到探索。为了确定对疾病进展至关重要的 microRNAs，我们使用定量聚合酶链反应 (qPCR) 阵列测量了 19 例原发性 CRC 肿瘤和同步肝转移中的 microRNA 表达。我们确定了 16 个在原发性肿瘤和肝转移之间表达差异显著的 microRNAs，这些 microRNAs通过层次聚类区分了原发性肿瘤和肝转移。原发性肿瘤和转移性肿瘤中表达的 microRNAs 组合与生存相关，但这些特征没有共同的 microRNAs。我们发现与原发性肿瘤相比，miR-210 和 miR-133b 在肝转移中的表达增加与生存率降低相关。我们提出，评估每个患者的原发性和转移性肿瘤之间表达的变化可能会导致更好的生物标志物开发。
